SCHEMBL1368994

SCHEMBL1368994

COC1(C2CC2)CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 7/20 0.49
OPRK1 P41145 6/20 0.49
OPRL1 P41146 6/20 0.49
CYP2D6 P10635 9/20 0.48
CYP3A4 P08684 8/20 0.48
CYP2C9 P11712 6/20 0.48
CYP2C19 P33261 3/20 0.48
OPRD1 P41143 5/20 0.48
USP2 O75604 3/20 0.47
CYP1A2 P05177 2/20 0.47
NPSR1 Q6W5P4 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45
HIF1A Q16665 3/20 0.45
ALOX15 P16050 1/20 0.44
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CHRM1 P11229 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL70939 0.76 NPSR1 (0.54) OPRM1OPRK1OPRL1CYP2D6CYP3A4
SCHEMBL70986 0.75 OPRM1 (0.49) OPRM1OPRK1OPRL1CYP2D6CYP3A4
SCHEMBL75647 0.75 OPRL1 (0.71) OPRM1OPRK1OPRL1CYP2D6CYP3A4
SCHEMBL75677 0.75 OPRM1 (0.53) OPRM1OPRK1OPRL1CYP2D6CYP3A4
Hydrochloric Acid SCHEMBL61570 0.73 OPRM1 (0.51) OPRM1OPRK1OPRL1CYP2D6CYP3A4
Hydrochloric Acid SCHEMBL62422 0.73 OPRL1 (0.69) OPRM1OPRK1OPRL1CYP2D6CYP3A4
SCHEMBL10047375 0.71 NPSR1 (0.61) OPRM1OPRK1OPRL1CYP2D6CYP3A4
SCHEMBL14742155 0.70 CYP3A4 (0.69) OPRM1OPRK1OPRL1CYP2D6CYP3A4
SCHEMBL17542448 0.70 OPRM1 (0.50) OPRM1OPRK1OPRL1CYP2D6CYP3A4
SCHEMBL31741187 0.69 NPSR1 (0.47) OPRM1OPRK1OPRL1CYP2D6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673891-B2 Aminopyrazine derivative and medicine NIPPON SHINYAKU CO., LTD. (JP) 2014-03-18 US disclosed
EP-2394999-B1 AMINOPYRAZINE DERIVATIVE AND MEDICINE NIPPON SHINYAKU CO LTD (JP) 2014-01-29 EP disclosed
US-8586591-B2 Aminopyrazine derivative and medicine NIPPON SHINYAKU CO., LTD. (JP) 2013-11-19 US disclosed
US-20130131082-A1 Aminopyrazine Derivative and Medicine NIPPON SHINYAKU CO., LTD (JP) 2013-05-23 US disclosed
EP-2394999-A1 AMINOPYRAZINE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2011-12-14 EP disclosed
US-20110288065-A1 AMINOPYRAZINE DERIVATIVE AND MEDICINE NIPPON SHINYAKU CO., LTD. (JP) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131082-A1 Aminopyrazine Derivative and Medicine MC2R, AGTR2, AGTR1 OPRM1 102/4885OPRK1 249/4885OPRL1 194/4885
US-20110288065-A1 AMINOPYRAZINE DERIVATIVE AND MEDICINE MC2R, CNR1, NPY2R OPRM1 76/4885OPRK1 182/4885OPRL1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.